Personal stories

Transforming cancer patients’ own cells into a targeted treatment is a complex and nuanced process. Jessica Torfs, director of Global CAR-T Supply Chain at Johnson & Johnson, explains what it takes to deliver this cutting-edge personalized therapy.

Through collaborations with Americares, Heart to Heart International, the American Red Cross, International Medical Corps and Sigma Theta Tau International Honor Society of Nursing, Johnson & Johnson, with support from the J&J Foundation, is standing with those who care for communities when catastrophe occurs.

Warm autoimmune hemolytic anemia is a rare, life-threatening disease that causes intense fatigue. Johnson & Johnson has a new therapy that targets the underlying drivers of the disease. Here, two patients—and Johnson & Johnson employees—share their journey, from symptoms and diagnosis to managing work and personal life.

This disease is highly treatable if caught early—but in its earliest stages, prostate cancer often has no symptoms, allowing it to develop without detection. Learn more about this common cancer and how Johnson & Johnson is innovating across both early-stage and advanced disease.

Jordan Schecter, M.D., leader of Johnson & Johnson’s end-to-end development strategy for multiple myeloma, shares insight on the evolving treatment landscape of this rare blood cancer.

Across New Jersey, more than one million people face food insecurity while millions of prepared meals go to waste each year. Through partnerships like the Meal Recovery Coalition, Johnson & Johnson is helping recover surplus food, strengthen local food systems and expand access to nutritious meals in communities where needs are greatest.

By combining deep understanding of technology and science with our people’s determination, Johnson & Johnson is powering the future of human health.